Enzyme-linked immunosorbent assay (ELISA) is a labeled immunoassay that is considered the gold standard of immunoassays. This immunological test is very sensitive and is used to detect and quantify substances, including antibodies, antigens, proteins, glycoproteins, and hormones. The detection of these products is accomplished by the complexing of antibodies and antigens to produce a measurable result. An antibody is a type of protein produced by an individual’s immune system. This protein type has specific regions that bind to antigens. An antigen is a protein that can come from some foreign source and, when bound to an antibody, induces a cascade of events through the body’s immune system. This interaction is utilized in ELISA testing and allows for the identification of specific protein antibodies and antigens, with only small amounts of a test sample. ELISA testing is used in the diagnosis of HIV infection, pregnancy tests, and blood typing, among others. This article will discuss the basic principles, procedures, and clinical significance of the ELISA.
Two different research teams invented the direct ELISA at the same time by scientists Eva Engvall and Peter Perlman and by Van Weemen and Schuurs. The ELISA was developed by the modification of the radioimmunoassay (RIA). This was done by conjugating tagged antigen and antibody with enzymes rather than radioactive iodine 125. The new method was first employed by determining the levels of IgG in rabbit serum. Within the same year, scientists were able to quantify human chorionic gonadotropin in urine by using horseradish peroxidase. Since then, the ELISA method has been used in many different fields of application and became a routine laboratory research and diagnostic method worldwide.
The first ELISA methodology involved chromogenic reporter molecules and substrates to generate observable color change that monitors the presence of antigen. Further advancement in the ELISA technique leads to the development of fluorogenic, quantitative PCR, and electrochemiluminescent reporters to generate signals. However, some of these techniques do not rely on using enzyme-linked substrates but non-enzymatic reporters that utilize the principle of ELISA.
The latest development, in 2012, was an ultrasensitive enzyme-based ELISA that manipulates nanoparticles as chromogenic reporters. This technique can generate a color signal visible by naked-eye, with blue color for positive results and red color for negative results. However, this method is qualitative and hence can determine only the presence or absence of an analyte and not its concentration.
ELISAs are performed in polystyrene plates, typically in 96-well plates that are coated to bind protein very strongly. Depending on the ELISA type, testing requires a primary and/or secondary detection antibody, analyte/antigen, coating antibody/antigen, buffer, wash, and substrate/chromogen. The primary detection antibody is a specific antibody that only binds to the protein of interest, while a secondary detection antibody is a second enzyme-conjugated antibody that binds a primary antibody that is not enzyme-conjugated.
There are four main general steps to completing an ELISA immunoassay. These steps are:
Detection is carried out by the addition of a substrate that can generate a color. There are many substrates available for use in ELISA detection. However, the most commonly used horseradish peroxidase (HRP) and alkaline phosphatase (ALP). The substrate for HRP is hydrogen peroxide and results in a blue color change. ALP measures the yellow color of nitrophenol after room temperature incubation periods of 15to 30 minutes and usually uses P-Nitrophenyl-phosphate (pNPP) as its substrate.
Between each of the above four steps is a “wash” of the plate using a buffer, such as phosphate-buffered saline (PBS) and a non-ionic detergent, to remove unbound material. The wells are washed two or more times during each wash step, depending on the specific protocol being followed.
In the ELISA protocol, usually, a serial dilution of concentrations is placed in the wells of the plate. After the results are measured, a standard curve from the serial dilutions data is plotted with a concentration on the x-axis using a log scale and absorbance on the y-axis using a linear scale.
There are four major types of ELISA:
Both direct and indirect ELISAs begin with the coating of antigen to the ELISA plates. The first binding step involves the addition of antigen to the plates, which is incubated for one hour at 37°C or can be incubated at 4°C overnight. Once the incubation step is completed, the next step is to wash the plates of any potential unbound antibody and block any unbound sites on the ELISA plate using agents like BSA, ovalbumin, aprotinin, or other animal proteins. This second step is important because it prevents the binding of any non-specific antibodies to the plate and minimizes false-positive results. After the addition of the buffer, the plate is rewashed, and a selected enzyme-conjugated primary detection antibody is added. The plate is further incubated for one hour.
In a direct ELISA, the primary detection antibody binds directly to the protein of interest. Next, the plate is rewashed to remove any unbound antibody and followed by the addition of a substrate/chromophore, such as alkaline phosphatase (AP) or Horseradish Peroxidase (HRP) to the plate, which results in a color change. The color change of the sample occurs by either the hydrolysis of phosphate groups from the substrate by AP or by the oxidation of substrates by HRP. The advantages of using direct ELISA include the elimination of secondary antibody cross-reactivity, and due to fewer steps, it is rapid as compared to indirect ELISA. Its disadvantages include its low sensitivity when compared to the other types of ELISA and its high cost of reaction.
The steps of the indirect ELISA are identical to the direct ELISA, with the exception of an additional wash step and the types of antibody added after the buffer is removed. Indirect ELISA requires two antibodies, a primary detection antibody that sticks to the protein of interest, and a secondary enzyme-linked antibody that is complementary to the primary antibody. The primary antibody is added first, followed by a wash step, and then the enzyme-conjugated secondary antibody is added and incubated. After this, the steps are the same as the direct ELISA, which includes a wash step, the addition of substrate, and detection of a color change.
The indirect ELISA has a higher sensitivity when compared to the direct ELISA. It is also less expensive and more flexible due to the many possible primary antibodies that can be used. The only major disadvantage with this type of ELISA is the risk of cross-reactivity between the secondary detection antibodies.
The sandwich ELISA, unlike direct and indirect ELISA, begins with a capture antibody coated onto the wells of the plate. It is termed as “sandwich” because the antigens are sandwiched between two layers of antibodies (capture and detection antibodies). After the addition of the capture antibody to the plates, the plates are then covered and incubated overnight at 4°C. Once the coating step is complete, the plates are washed with PBS, then buffered/blocked with BSA. The buffer washes are carried out for at least 1-2 hours at room temperature. Finally, the plate is washed with PBS once again before the addition of the antigen.
The antigen of interest is then added to the plates to bind to the capture antibody and incubated for 90 min at 37°C. The plate is rewashed, and the primary detection antibody is then added to the plate and incubated for another 1 to 2 hours at room temperature followed by a buffer wash. Then the secondary enzyme-conjugated antibody is added and incubated for another 1 to 2 hours. The plate is rewashed, and the substrate is added to produce a color change. The sandwich ELISA has the highest sensitivity among all the ELISA types. The major disadvantages of this type of ELISA are the time and expense and the necessary use of “matched pair” (divalent/multivalent antigen), and secondary antibodies.
The competitive ELISA tests for the presence of an antibody specific for antigens in the test serum. This type of ELISA utilizes two specific antibodies, an enzyme-conjugated antibody and another antibody that is present in the test serum (if the serum is positive). Combining the two antibodies into the wells will allow for a competition for binding to antigen. The presence of a color change means that the test is negative because the enzyme-conjugated antibody bound the antigens (not the antibodies of the test serum). The absence of color indicates a positive test, and the presence of antibodies in the test serum. The competitive ELISA has a low specificity and cannot be used in dilute samples. Though the benefits are that there is less sample purification needed, it can measure a large range of antigens in a given sample, can be used for small antigens, and has low variability.
Detect and measure the presence of antibodies in the blood
Detect and estimate the levels of tumor markers
Detect and estimate hormone levels
Tracking disease outbreaks.
Detecting past exposures.
Screening donated blood for possible viral contaminants.
Detecting drug abuse.
Factors that can interfere with appropriate ELISA testing can occur at any phase of the testing process beginning with specimen collection. The quality and integrity of the assay plate, coating buffer, capture antibody, blocking buffer, target antigen, detection antibody, enzyme conjugate, washes, substrate, signal detection can all interfere with proper ELISA testing. Some of the factors that can interfere in testing are the following:
Data gathered from ELISA tests can be quantitative, qualitative, or semiquantitative. The quantitative concentration results are plotted and compared to a standard curve. The qualitative results confirm or deny the presence of a particular antigen/antibody in a sample. The semiquantitative results compare the intensity of the signals, which can be used to compare relative antigen levels in a sample. Once color changes are measured from the assay, the results are graphed either on paper or software. Typically, the graph compares optical density to log concentration, which gives a sigmoidal curve. Known concentrations give the standard curve of the graph, and measurement of unknowns can then occur when sample values are compared to the linear portion of the graphed standard curve.
ELISAs can be used in many settings, including rapid antibody screening tests for Human immunodeficiency virus (HIV), detection of other viruses, bacteria, fungi, autoimmune diseases, food allergens, blood typing, presence of the pregnancy hormone hCG, laboratory and clinical research, forensic toxicology and many other diagnostic settings.
In HIV testing, a blood or saliva specimen is collected for testing typically by the use of indirect ELISA-based tests. The ELISA is a screening tool for HIV detection, but not diagnostic. Diagnosis requires further testing by Western blot due to potential false positives. Another virus, Molluscum contagiosum virus (MCV) that commonly infects the skin of children and young adults, can be detected by ELISA testing. ELISA testing in this setting is currently being evaluated for the assessment of global MCV seroprevalence.
ELISA has also been used in the detection of desmogleins 1 and 3 and bullous pemphigoid antigen 180 autoantibodies, which are implicated in pemphigus and bullous pemphigoid autoimmune blistering diseases respectively. In food allergy, the evolution of the ELISA has played an important role in allergy research and diagnosis. Ultrasensitive ELISA variations that have been developed to detect quantities of allergens in the scale of picograms. This is important because of the life-threatening role that food allergies can have on a public health scale.
ELISA testing is an important part of medical care and scientific research. Collaboration between scientists, laboratory technicians, phlebotomists, physicians, nurses, and other medical professionals is necessary for appropriate specimen collection, testing, interpretation, diagnosis, and effective patient education and treatment planning. ELISA technologies continue to grow and play a major role in clinical research allowing for the development of more diagnostic and screening tests. The continued evolution of ELISA testing is promising for the future of medicine and has allowed for the improvement of early diagnosis of HIV and the detection of pregnancy.
|||Aydin S, A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. Peptides. 2015 Oct; [PubMed PMID: 25908411]|
|||Engvall E, The ELISA, enzyme-linked immunosorbent assay. Clinical chemistry. 2010 Feb; [PubMed PMID: 19850633]|
|||Shah K,Maghsoudlou P, Enzyme-linked immunosorbent assay (ELISA): the basics. British journal of hospital medicine (London, England : 2005). 2016 Jul; [PubMed PMID: 27388394]|
|||Konstantinou GN, Enzyme-Linked Immunosorbent Assay (ELISA). Methods in molecular biology (Clifton, N.J.). 2017; [PubMed PMID: 28315213]|
|||Leng SX,McElhaney JE,Walston JD,Xie D,Fedarko NS,Kuchel GA, ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. The journals of gerontology. Series A, Biological sciences and medical sciences. 2008 Aug [PubMed PMID: 18772478]|
|||Gelkop S,Sobarzo A,Brangel P,Vincke C,Romão E,Fedida-Metula S,Strom N,Ataliba I,Mwiine FN,Ochwo S,Velazquez-Salinas L,McKendry RA,Muyldermans S,Lutwama JJ,Rieder E,Yavelsky V,Lobel L, The Development and Validation of a Novel Nanobody-Based Competitive ELISA for the Detection of Foot and Mouth Disease 3ABC Antibodies in Cattle. Frontiers in veterinary science. 2018 [PubMed PMID: 30370272]|
|||de la Rica R,Stevens MM, Plasmonic ELISA for the ultrasensitive detection of disease biomarkers with the naked eye. Nature nanotechnology. 2012 Dec [PubMed PMID: 23103935]|
|||Kohl TO,Ascoli CA, Direct Competitive Enzyme-Linked Immunosorbent Assay (ELISA). Cold Spring Harbor protocols. 2017 Jul 5; [PubMed PMID: 28679705]|
|||Kohl TO,Ascoli CA, Indirect Immunometric ELISA. Cold Spring Harbor protocols. 2017 May 1; [PubMed PMID: 28461658]|
|||Kohl TO,Ascoli CA, Immunometric Double-Antibody Sandwich Enzyme-Linked Immunosorbent Assay. Cold Spring Harbor protocols. 2017 Jun 1; [PubMed PMID: 28572188]|
|||Tighe PJ,Ryder RR,Todd I,Fairclough LC, ELISA in the multiplex era: potentials and pitfalls. Proteomics. Clinical applications. 2015 Apr; [PubMed PMID: 25644123]|
|||Kuo HT,Yeh JZ,Wu PH,Jiang CM,Wu MC, Application of immunomagnetic particles to enzyme-linked immunosorbent assay (ELISA) for improvement of detection sensitivity of HCG. Journal of immunoassay [PubMed PMID: 22963487]|
|||[PubMed PMID: 29300967]|
|||[PubMed PMID: 26042815]|
|||Sherwani S,Chowdhury M,Bugert JJ, ELISA for Molluscum Contagiosum Virus. Current protocols in microbiology. 2017 Nov 9; [PubMed PMID: 29120484]|
|||Atzori L,Deidda S,Aste N, Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia. 2008 Feb; [PubMed PMID: 18833046]|
|||[PubMed PMID: 27338488]|